Merus N.V. (MRUS)
Dec 30, 2025 - MRUS was delisted (reason: acquired by GMAB)
81.00
-0.50 (-0.61%)
Inactive · Last trade price
on Dec 16, 2025
Merus Employees
As of December 31, 2024, Merus had 321 total employees, including 260 full-time and 61 part-time employees. The number of employees increased by 92 or 40.17% compared to the previous year.
Employees
321
Change (1Y)
92
Growth (1Y)
40.17%
Revenue / Employee
$176,343
Profits / Employee
-$1,187,336
Market Cap
6.83B
Employees Chart
MRUS News
- 2 months ago - Merus Power Delivers an Energy Storage System for Extreme Arctic Conditions - Business Wire
- 4 months ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 5 months ago - Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PRNewsWire
- 6 months ago - Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - GlobeNewsWire
- 6 months ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 6 months ago - Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. - GlobeNewsWire
- 7 months ago - Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 7 months ago - Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire